Home Companies Catalysts Deep Dives
Lokelma sodium zirconium cyclosilicate APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2018-05-18
US LOE2032-01-01
Peak Sales Est$1000M
Formulations[{"id":"lokelma-oral","doses":"5g, 10g powder","route":"Oral","setting":"PATIENT_SELF","frequency":"
Companies
AZN (ORIGINATOR)100%
Mechanism: Potassium binder
Expert: Non-absorbed zirconium silicate that selectively captures potassium ions in exchange for sodium and hydrogen throughout the GI tract.
Everyday: Absorbs excess potassium in the gut to lower dangerously high potassium levels.
Targets: []
Revenue History
PeriodRevenue ($M)
2023$512M
2024$621M
Q1 2025$175M
Programs (1)
IndicationStageKey StudyRegional Status
HyperkalemiaAPPROVEDHARMONIZE[{"stage":"APPROVED","region":"US","approval_date":"2018-05-18"},{"stage":"APPRO
Notes
Potassium binder.
Data from Supabase · Updated 2026-03-24